Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNNI3K | Q59H18 | 13/20 | 0.57 |
| ▸ | BRAF | P15056 | 2/20 | 0.55 |
| ▸ | EGFR | P00533 | 3/20 | 0.54 |
| ▸ | JAK1 | P23458 | 3/20 | 0.53 |
| ▸ | JAK3 | P52333 | 3/20 | 0.53 |
| ▸ | SYK | P43405 | 1/20 | 0.53 |
| ▸ | BRD4 | O60885 | 3/20 | 0.52 |
| ▸ | BUB1B | O60566 | 1/20 | 0.52 |
| ▸ | JAK2 | O60674 | 1/20 | 0.52 |
| ▸ | RET | P07949 | 1/20 | 0.52 |
| ▸ | BRD2 | P25440 | 1/20 | 0.52 |
| ▸ | WEE1 | P30291 | 1/20 | 0.52 |
| ▸ | FLT3 | P36888 | 1/20 | 0.52 |
| ▸ | BRD3 | Q15059 | 1/20 | 0.52 |
| ▸ | BRDT | Q58F21 | 1/20 | 0.52 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.52 |
| ▸ | BTK | Q06187 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17916035 | 0.89 | JAK1 (0.62) | EGFRJAK1JAK3SYKJAK2 | |
| SCHEMBL17916014 | 0.89 | BRD4 (0.66) | TNNI3KBRAFEGFRJAK1JAK3 | |
| SCHEMBL17915956 | 0.89 | BRD4 (0.66) | TNNI3KBRAFEGFRJAK1JAK3 | |
| SCHEMBL10260435 | 0.89 | GAK (0.55) | TNNI3KBRAFEGFRJAK1JAK3 | |
| SCHEMBL270501 | 0.89 | JAK1 (0.56) | TNNI3KBRAFEGFRJAK1JAK3 | |
| SCHEMBL17915944 | 0.88 | JAK3 (0.67) | EGFRJAK1JAK3SYKBRD4 | |
| SCHEMBL309668 | 0.85 | TNNI3K (0.61) | TNNI3KBRAFEGFR | |
| SCHEMBL17915906 | 0.84 | BRD4 (0.63) | TNNI3KBRAFEGFRJAK1JAK3 | |
| SCHEMBL17915907 | 0.83 | JAK3 (0.49) | EGFRJAK1JAK3SYKBRD4 | |
| SCHEMBL17915905 | 0.82 | KDM4E (0.54) | TNNI3KBRAFEGFRJAK1JAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110212077-A1 | BI-ARYL META-PYRIMIDINE INHIBITORS OF KINASES | TARGEGEN, INC. (US) | 2011-09-01 | — | — | US | disclosed |
| US-7825246-B2 | Bi-aryl meta-pyrimidine inhibitors of kinases | TARGEGEN, INC. (US) | 2010-11-02 | — | — | US | disclosed |
| US-20070259904-A1 | Bi-aryl meta-pyrimidine inhibitors of kinases | TARGEGEN, INC. (US) | 2007-11-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070259904-A1 | Bi-aryl meta-pyrimidine inhibitors of kinases | JAK2, TYK2, JAK3 | TNNI3K 94/4885BRAF 40/4885EGFR 181/4885 |
| US-20110212077-A1 | BI-ARYL META-PYRIMIDINE INHIBITORS OF KINASES | JAK2, TYK2, JAK3 | TNNI3K 94/4885BRAF 40/4885EGFR 181/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.